~~<i id='2F7A9F3FBC'><strike id='2F7A9F3FBC'><tt id='2F7A9F3FBC'><pre id='2F7A9F3FBC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：fashion 2025-09-02 05:48:18 - browse：96253

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout LOUD podcast: brain research, obesity drug sales, Novartis

hotspot

focus

knowledge

hotspot

AuthorEmmiHermanstandsbehindhersister,Marcie,whosurvivedmeaslesencephalitis,assheplaysthepiano.Court

WSS

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Study: Adult vaccinations pay for themselves in societal benefits

Sanofi strikes deal with Novavax, boosting the vaccine maker

When prostate cancer spreads, where it goes matters

Dairy farmers resist CDC push for PPE against bird flu virus

entertainment

explore

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Sports medicine is finally prioritizing gender equality

When prostate cancer spreads, where it goes matters

What does generative AI mean for health care? We asked experts

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Wildfire smoke exposes gaps in outdoor worker protections

When prostate cancer spreads, where it goes matters

In Memoriam: Notable people who died in 2023

Shionogi licenses Pompe disease therapy from Maze Therapeutics

focus

Use wet bulb globe temperature, not heat index, to protect workers

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Study: AI not yet building 'n

H5N1 communication has been strictly for the birds

Google says AlphaFold 3 can map a vast universe of biomolecules

focus

knowledge

knowledge

hotspot